Spick Claudio, Polanec Stephan H, Mitterhauser Markus, Wadsak Wolfgang, Anner Philip, Reiterits Bettina, Haug Alexander R, Hacker Marcus, Beheshti Mohsen, Karanikas Georgios
Division of General and Pediatric Radiology, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria.
Anticancer Res. 2015 Dec;35(12):6787-91.
To evaluate the diagnostic accuracy of (11)C-acetate positron-emission tomography (PET) in the detection of bone metastasis in patients with prostate cancer with biochemical recurrence.
Ninety patients (100%) with rising prostate-specific antigen (PSA) levels (>0.2 ng/ml) after radical prostatectomy, who had both (11)C-acetate PET and bone scan performed and who had clinical follow-up/imaging follow-up for bone metastasis, considered a gold standard, were included. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for (11)C-acetate PET were calculated on a per-patient basis.
(11)C-Acetate PET and (99m)Tc-dicarboxypropane-diphosphonate findings were concordant in 84 (93.3%) patients [35 (38.9%) true-positive, 49 (54.4%) true-negative]. Discordant findings were observed in six patients (6.7%). (11)C-Acetate PET presented two (2.2%) false-positive and four (4.4%) false-negative findings. The sensitivity, specificity, PPV, and NPV for (11)C-acetate PET were 89.7%, 96.1%, 94.6%, and 92.2%, respectively. The median PSA of patients with multiple skeletal metastases (median=23.64 ng/ml, range=3.16-551.1 ng/ml) differed significantly (p=0.018) from that of patients with focal metastases (median=6.7 ng/ml, range=0.31-12.8 ng/ml).
(11)C-Acetate PET is a useful tool for patients with prostate cancer with biochemical recurrence, as it can depict multiple sites of recurrence and in particularly shows a high diagnostic value equivalent to that of bone scan for the detection of bone metastases.
评估¹¹C-乙酸盐正电子发射断层扫描（PET）在检测生化复发的前列腺癌患者骨转移中的诊断准确性。
纳入90例（100%）前列腺癌根治术后前列腺特异性抗原（PSA）水平升高（>0.2 ng/ml）的患者，这些患者均接受了¹¹C-乙酸盐PET和骨扫描检查，并对骨转移进行了临床随访/影像学随访，将其视为金标准。基于每位患者计算¹¹C-乙酸盐PET的敏感性、特异性、阳性预测值（PPV）和阴性预测值（NPV）。
¹¹C-乙酸盐PET与⁹⁹mTc-二羧丙烷二膦酸盐检查结果在84例（93.3%）患者中一致[35例（38.9%）真阳性，49例（54.4%）真阴性]。6例（6.7%）患者出现不一致的结果。¹¹C-乙酸盐PET出现2例（2.2%）假阳性和4例（4.4%）假阴性结果。¹¹C-乙酸盐PET的敏感性、特异性、PPV和NPV分别为89.7%、96.1%、94.6%和92.2%。多发骨转移患者的PSA中位数（中位数=23.64 ng/ml，范围=3.16 - 551.1 ng/ml）与局灶性转移患者的PSA中位数（中位数=6.7 ng/ml，范围=0.31 - 12.8 ng/ml）有显著差异（p = 0.018）。
¹¹C-乙酸盐PET对于生化复发的前列腺癌患者是一种有用的工具，因为它可以描绘多个复发部位，尤其在检测骨转移方面显示出与骨扫描相当的高诊断价值。
